|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
|
US4237224A
(en)
|
1974-11-04 |
1980-12-02 |
Board Of Trustees Of The Leland Stanford Jr. University |
Process for producing biologically functional molecular chimeras
|
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
WO1981001145A1
(en)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Hydrolytic enzyme-activatible pro-drugs
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US5182368A
(en)
|
1986-06-13 |
1993-01-26 |
Ledbetter Jeffrey A |
Ligands and methods for augmenting B-cell proliferation
|
|
US5247069A
(en)
|
1986-06-13 |
1993-09-21 |
Oncogen |
Ligands and methods for augmenting B-cell proliferation
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
GB8705477D0
(en)
|
1987-03-09 |
1987-04-15 |
Carlton Med Prod |
Drug delivery systems
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5264586A
(en)
|
1991-07-17 |
1993-11-23 |
The Scripps Research Institute |
Analogs of calicheamicin gamma1I, method of making and using the same
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
JP3720353B2
(ja)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
多価および多重特異性の結合タンパク質、それらの製造および使用
|
|
US6838254B1
(en)
|
1993-04-29 |
2005-01-04 |
Conopco, Inc. |
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
|
|
KR960704576A
(ko)
|
1993-10-01 |
1996-10-09 |
크리스토퍼 엘. 와이트 |
CD40에 대한 항체(Antibodies to CD40)
|
|
DE69433820T2
(de)
|
1993-12-23 |
2005-06-23 |
Immunex Corp., Seattle |
Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
GB9425060D0
(en)
|
1994-12-13 |
1995-02-08 |
Univ Birmingham |
Carcinoma treatment
|
|
US5675063A
(en)
|
1995-02-28 |
1997-10-07 |
Loyola University Of Chicago |
Immortalized rabbit hybridoma fusion partner
|
|
AU699291B2
(en)
|
1995-03-01 |
1998-11-26 |
Immunex Corporation |
Method for stimulating an immune response
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
EP1033406A4
(en)
*
|
1997-10-27 |
2005-03-09 |
Sumitomo Electric Industries |
INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
|
|
US6051228A
(en)
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
KR100301796B1
(ko)
*
|
1998-10-01 |
2001-09-06 |
성재갑 |
면역억제능이 있는 항-씨디40 리간드 모노클로날 항체
|
|
US6680176B2
(en)
|
1999-05-17 |
2004-01-20 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Identification of candidate ligands which modulate antigen presenting cells
|
|
US20030118588A1
(en)
|
1999-05-22 |
2003-06-26 |
Linda Diehl |
Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
AU2001236621B2
(en)
|
2000-02-01 |
2006-06-15 |
Mycenax Biotech Inc. |
Cd40-binding apc-activating molecules
|
|
BR0110190A
(pt)
|
2000-04-19 |
2003-12-30 |
Tanox Inc |
Antagonistas de cd40 para uso em tratamento de psorìase e outras condições inflamatórias de pele
|
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
|
KR100643818B1
(ko)
|
2000-05-08 |
2006-11-10 |
셀덱스 쎄라퓨틱스, 인크. |
수상세포에 대한 인간 모노클로날 항체
|
|
EP2011802A3
(en)
|
2001-04-27 |
2009-04-15 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-CD40 monoclonal antibody
|
|
JP4025881B2
(ja)
*
|
2001-04-27 |
2007-12-26 |
キリンファーマ株式会社 |
抗ｃｄ４０モノクローナル抗体
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
AU2003217912A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
ES2349777T3
(es)
*
|
2003-01-22 |
2011-01-11 |
Glycart Biotechnology Ag |
Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de fc y función efectora.
|
|
JP4746552B2
(ja)
*
|
2003-11-04 |
2011-08-10 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
|
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
KR101223373B1
(ko)
*
|
2003-12-25 |
2013-01-16 |
교와 핫꼬 기린 가부시키가이샤 |
항 ｃｄ４０ 항체의 변이체
|
|
EA012464B1
(ru)
|
2004-08-04 |
2009-10-30 |
Эпплайд Молекьюлар Эволюшн, Инк. |
Антитело против cd20 и его применение
|
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
|
CA2595682A1
(en)
|
2005-01-31 |
2006-08-03 |
Ablynx N.V. |
Method for generating variable domain sequences of heavy chain antibodies
|
|
US20060257359A1
(en)
|
2005-02-28 |
2006-11-16 |
Cedric Francois |
Modifying macrophage phenotype for treatment of disease
|
|
WO2006105338A2
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
JP5208730B2
(ja)
|
2005-05-18 |
2013-06-12 |
ノバルティス アーゲー |
Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
|
|
PL1889065T3
(pl)
|
2005-05-18 |
2013-12-31 |
Novartis Ag |
Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
|
|
EP1885399B1
(en)
|
2005-05-26 |
2010-10-20 |
Seattle Genetics, Inc. |
Humanized anti-cd40 antibodies and their methods of use
|
|
US7429487B2
(en)
|
2005-07-05 |
2008-09-30 |
Epitomics, Inc. |
Fusion partner for production of monoclonal rabbit antibodies
|
|
WO2007041238A2
(en)
|
2005-09-29 |
2007-04-12 |
Stratagene California |
Methods of identification and use of gene signatures
|
|
JP2009517339A
(ja)
*
|
2005-11-01 |
2009-04-30 |
ノバルティス アーゲー |
抗ｃｄ４０抗体の使用
|
|
JP2009513712A
(ja)
|
2005-11-01 |
2009-04-02 |
ノバルティス アーゲー |
抗ｃｄ４０抗体の使用
|
|
US10155816B2
(en)
|
2005-11-28 |
2018-12-18 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
AU2006329944A1
(en)
|
2005-12-09 |
2007-07-05 |
Seattle Genetics, Inc. |
Methods of using CD40 binding agents
|
|
EP2465510B1
(en)
|
2006-10-19 |
2018-11-28 |
Baylor College Of Medicine |
Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
EP2097097B1
(en)
|
2006-12-01 |
2018-05-30 |
E. R. Squibb & Sons, L.L.C. |
Antibodies, in particular human antibodies, that bind cd22 and uses thereof
|
|
CN101605906A
(zh)
|
2006-12-14 |
2009-12-16 |
梅达雷克斯公司 |
结合cd70的人类抗体及其用途
|
|
JP5357778B2
(ja)
*
|
2007-01-23 |
2013-12-04 |
ゼンコー・インコーポレイテッド |
最適化ｃｄ４０抗体および前記を使用する方法
|
|
US20080241065A1
(en)
|
2007-03-27 |
2008-10-02 |
Benaron David A |
Systems and methods for the detection and analysis of in vivo circulating cells, entities, and nanobots
|
|
KR20100028571A
(ko)
|
2007-05-21 |
2010-03-12 |
앨더 바이오파마슈티컬즈, 인코포레이티드 |
신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
|
|
US20090238825A1
(en)
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
|
EP1997832A1
(en)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against Claudin-18 for treatment of cancer
|
|
AU2008260498B2
(en)
*
|
2007-05-30 |
2012-11-29 |
Xencor, Inc. |
Methods and compositions for inhibiting CD32b expressing cells
|
|
EP2245065A1
(en)
|
2008-01-23 |
2010-11-03 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
KR20110036618A
(ko)
|
2008-07-16 |
2011-04-07 |
베일러 리서치 인스티튜트 |
극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
|
|
CN102170908A
(zh)
|
2008-08-29 |
2011-08-31 |
莱顿大学医学中心附属莱顿教学医院 |
向个体的肿瘤引流淋巴结递送cd40激动剂
|
|
JP2012511014A
(ja)
|
2008-12-05 |
2012-05-17 |
エイエルエス・セラピー・デベロップメント・インスティテュート |
神経変成疾患を治療する方法
|
|
AU2010222942B2
(en)
|
2009-03-10 |
2013-01-10 |
Baylor Research Institute |
Anti-CD40 antibodies and uses thereof
|
|
CA2758523C
(en)
|
2009-04-18 |
2019-03-12 |
Genentech, Inc. |
Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
|
|
EP2993188B1
(en)
|
2009-04-20 |
2020-08-19 |
Kyowa Kirin Co., Ltd. |
Anti cd40 antibody containing igg2 having three amino acid mutations introduced therein
|
|
US9128101B2
(en)
|
2010-03-01 |
2015-09-08 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarkers for theranostics
|
|
JP2013528357A
(ja)
*
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
NZ602020A
(en)
|
2010-03-31 |
2014-05-30 |
Boehringer Ingelheim Int |
Anti-cd40 antibodies
|
|
US20110280862A1
(en)
|
2010-05-14 |
2011-11-17 |
The University Of Hong Kong |
Gep and drug transporter regulation, cancer therapy and prognosis
|
|
US10131875B2
(en)
|
2010-08-04 |
2018-11-20 |
Duke University |
Regulatory B cells and their uses
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
CA2824278C
(en)
|
2010-12-20 |
2022-09-20 |
The Rockefeller University |
Modulating agonistic tnfr antibodies
|
|
US9475879B2
(en)
*
|
2011-04-21 |
2016-10-25 |
Bristol-Myers Squibb Company |
Antibody polypeptides that antagonize CD40
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
WO2014046619A1
(en)
|
2012-09-18 |
2014-03-27 |
Agency For Science, Technology And Research |
Grouping for classifying gastric cancer
|
|
CN104918957B
(zh)
|
2012-10-30 |
2018-11-16 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
US9209965B2
(en)
|
2014-01-14 |
2015-12-08 |
Microsemi Semiconductor Ulc |
Network interface with clock recovery module on line card
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
KR102443258B1
(ko)
|
2014-08-12 |
2022-09-14 |
엘리게이터 바이오사이언스 에이비 |
항 cd40 항체에 의한 병용 치료제
|
|
US20170355768A1
(en)
|
2014-12-04 |
2017-12-14 |
Bristol-Myers Squibb Company |
Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
|
|
US20180223368A1
(en)
|
2015-03-18 |
2018-08-09 |
Memorial Sloan Ketteting Cancer Center |
Methods for diagnosing and treating follicular lymphoma
|
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
|
KR102671348B1
(ko)
|
2015-06-29 |
2024-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd40에 대한 항체
|
|
AU2016304597B2
(en)
|
2015-08-06 |
2022-10-06 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for tumor therapy
|
|
JP2019534292A
(ja)
|
2016-11-02 |
2019-11-28 |
アペクシジェン， インコーポレイテッド |
組み合わせた抗ｃｄ４０抗体および使用方法
|
|
US11852631B2
(en)
|
2018-01-19 |
2023-12-26 |
Dana-Farber Cancer Institute, Inc. |
Biomarkers predictive of anti-immune checkpoint response
|
|
US20240252633A1
(en)
|
2021-06-03 |
2024-08-01 |
Apexigen America, Inc. |
Methods of treating cancer with cd-40 agonists
|
|
US20240336693A1
(en)
|
2021-08-10 |
2024-10-10 |
Apexigen, Inc. |
Biomarkers for cd40 agonist therapy
|